14 completed, 5 unknown, 3 recruiting, 2 active not recruiting. 28 Phase 3, 9 Phase 2.
Follow Anorexia: new trials by email Literature Review of Anorexia trials Research Report on Anorexia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| Pediatric Prolonged-Release Melatonin for Sleep Disturbances in Children and Adolescents With Anorexia Nervosa (MELSom-ANOREXIA) Pediatric Prolonged-Released Melatonin (PedPRM), Placebo - Anorexia Nervosa, Sleep Disorders in Children | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 120 | 2026-09-01 | 2026-05-08 |
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-09-22 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Pfizer | 982 | 2025-10-03 | 2026-10-14 |
| Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets - Functional Dyspepsia | Phase 3 | Completed | Abbott | 564 | 2024-02-28 | 2026-04-03 |
| Olanzapine for Cancer Related Anorexia-cachexia Syndrome Olanzapine 2.5 MG, Olanzapine 5 MG, Placebo - Anorexia, Cachexia | Phase 3 | Unknown | Mahidol University | 138 | 2024-01-22 | 2024-07-24 |
| Effectiveness of Cannabinoids on Appetite in Scleroderma CBD oil, Placebo - Systemic Sclerosis, Malnutrition | Phase 3 | Completed | Khon Kaen University | 30 | 2022-11-09 | 2025-02-20 |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients Olanzapine, Megestrol Acetate, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Anorexia | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 227 | 2022-01-03 | 2026-07-30 |
| Olanzapine Anorexia Cachexia Olanzapine 5 MG, Placebo - Anorexia | Phase 3 | Completed | Cairo University | 164 | 2021-12-25 | 2024-10-03 |
| Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Anamorelin Hydrochloride, Placebo, Questionnaire Administration - Anorexia, Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2018-11-27 | 2026-10-06 |
| The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers Acupuncture, Sham Acupuncture, Megestrol Acetate - Anorexia, Cancer Cachexia | Phase 2 / Phase 3 | Unknown | Xinqiao Hospital of Chongqing | 160 | 2015-12-01 | 2015-12-04 |
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients Nabilone, Placebo - Non-Small Cell Lung Cancer, Anorexia | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 78 | 2014-12-01 | 2016-08-31 |
| A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression Trazodone, Placebo - Depression | Phase 2 / Phase 3 | Completed | Lee's Pharmaceutical Limited | 382 | 2011-11-01 | 2014-10-16 |
| Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex Apevinat BC, Vitamin Complex - Lack of Appetite, Anorexia | Phase 3 | Unknown | MDCPharma Produtos Farmaceuticos LTDA | 74 | 2011-04-01 | 2011-02-14 |
| Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Olanzapine - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | Charite University, Berlin, Germany | 40 | 2011-03-01 | 2024-02-14 |
| Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate. Apetiviton BC - Inappetence | Phase 3 | Unknown | Cifarma Cientifica Farmaceutica Ltda | 150 | 2010-08-01 | 2010-05-19 |
| Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder Low Dose Fish Oil, High Dose Fish Oil - Major Depressive Disorder | Phase 2 / Phase 3 | Completed | University of Cincinnati | 20 | 2007-08-01 | 2016-05-27 |
| Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo - Anorexia, Cachexia | Phase 3 | Terminated | Par Pharmaceutical, Inc. | 4 | 2006-06-01 | 2016-05-02 |
| Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients Megestrol acetate concentrated suspension 110 mg/mL, Placebo - Anorexia, Cachexia | Phase 3 | Terminated | Par Pharmaceutical, Inc. | 5 | 2006-06-01 | 2016-06-23 |
Showing 20 of 28. Sign in to see all of them.
Cachexia (16) · Weight Loss (7) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Neoplasms (4) · Body Weight (3) · Fatigue (3) · Malnutrition (2) · Pancreatic Neoplasms (2) · Abdominal Pain (1) · Acquired Immunodeficiency Syndrome (1) · Amyotrophic Lateral Sclerosis (1) · Anorexia Nervosa (1) · Body Weight Changes (1)
Pathological Conditions, Signs and Symptoms (28) · Signs and Symptoms (28) · Signs and Symptoms, Digestive (28) · Body Weight Changes (16) · Thinness (16) · Body Weight (14) · Neoplasms by Site (11) · Weight Loss (10) · Neoplasms (9) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5)
Megestrol Acetate (8) · Olanzapine (4) · Acupuncture Therapy (1) · Ascorbic Acid (1) · Creatine (1) · Docetaxel (1) · Eicosapentaenoic Acid (1) · Etanercept (1) · Fish Oils (1) · Infliximab (1) · Melatonin (1) · Radiotherapy (1) · Trazodone (1) · anamorelin (1) · nabilone (1)
Alliance for Clinical Trials in Oncology (4) · M.D. Anderson Cancer Center (2) · Par Pharmaceutical, Inc. (2) · Wake Forest University Health Sciences (2) · AVEO Pharmaceuticals, Inc. (1) · Abbott (1) · Assistance Publique Hopitaux De Marseille (1) · Bristol-Myers Squibb (1) · Cairo University (1) · CatalYm GmbH (1) · Charite University, Berlin, Germany (1) · Cifarma Cientifica Farmaceutica Ltda (1) · Instituto Nacional de Cancerologia de Mexico (1) · Khon Kaen University (1) · Lee's Pharmaceutical Limited (1)
United States (15) · China (4) · France (3) · Germany (3) · Thailand (3) · Brazil (2) · Bulgaria (2) · Canada (2) · Italy (2) · Mexico (2) · Poland (2) · Spain (2) · United Kingdom (2) · Armenia (1) · Australia (1)
Aminah Jatoi, MD (5) · Lynn D Kramer, MD (2) · Bart Frizzell, MD (1) · Benjamin LI, Ph.D. (1) · Chaoting Zhao, MD (1) · Chingching Foocharoen, M.D. (1) · Edward G. Shaw, MD (1) · Felicio S Neto, Investigator (1) · Haiou Luo, PhD (1) · Janet Bull, MD (1) · Joaquim CS D' Azevedo, Investigator (1) · John N Mehanna, MD (1) · Kathryn M. Greven, MD (1) · M.Daud Nawabi, MD (1)
PMID 11786587, PMID 12457271, PMID 15197210, PMID 15778874, PMID 15857739, PMID 16376734, PMID 16408219, PMID 1666930, PMID 16849753, PMID 17589370, PMID 17674351, PMID 18402303, PMID 19665818, PMID 21343383, PMID 23439759, PMID 29550881, PMID 3774823, PMID 38197040, PMID 41137182, PMID 8035251, PMID 8558188
2025 (1), UG1CA189823 (1)